X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

4 things you need to know about the administration’s latest Part B proposal

By Nicole Longo  |    November 5, 2018
The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....   Read More

ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation

By Nicole Longo  |    October 9, 2018
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses, detailing how such schemes expose Americans to dangerous counterfeit medicines. The reporter...   Read More

PhRMA comments in response to request for information on competitive bidding program in Medicare Part B

By Nicole Longo  |    September 25, 2018
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule,...   Read More

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

By Nicole Longo  |    August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...   Read More

New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending

By Nicole Longo  |    August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...   Read More

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

GAO again recommends improvements to 340B program

By Nicole Longo  |    July 11, 2018
Over the years, the non-partisan Government Accountability Office (GAO) has reviewed various aspects of the 340B program, finding areas for improvement and providing recommendations. The latest...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

By Nicole Longo  |    June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...   Read More

Supreme Court decisions in two cases pave way for IPR reforms

By Nicole Longo  |    May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates